ARTICLE | Company News
Turing Pharmaceuticals infectious news
November 9, 2015 8:00 AM UTC
Turing CEO Martin Shkreli said in an interview the company will commit to a “modest” price reduction of about 10% for toxoplasmosis drug Daraprim pyrimethamine by year end. Shkreli also said he is considering discounts on the order of 25-50% for smaller hospitals that cannot afford to stock the dihydrofolate reductase (DHFR) inhibitor. The company said further discussions on Daraprim discounts are “premature.” ...